Back to News
FDA approves Priovant’s Lisraya for dermatomyositis treatment
Source: Investing.com
Article content is unavailable (HTTP 403), so no financial details, numbers, or market-moving information could be extracted.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.00
More News
- US forces disable ship ‘attempting to run’ Iran blockade in Gulf of Oman
- Middle East war, high debt levels to dominate IMF-World Bank meetings in Bangkok
- Attack on Saudi airport kills 12 people and wounds more than 300—the deadliest strike in any Gulf Arab country since the start of the Iran war
- Musk says Terrafab chip factory could outperform rivals despite challenges
- India’s Rupee Defense Raises Question of How Far RBI Will Go
- CBO chief warns it’s ‘probably not plausible’ that a strong economy alone can steady U.S. debt as 5%-6% growth is needed—more than Bessent’s 3% view